Madison Keats Divests LION biosciences AG Compound Library.

Contact: David Teifer, Managing Director Madison Keats (704) 377-4121 ext. 1018

April 1, 2003. CHARLOTTE, NC and CAMBRIDGE, MA -
Madison Keats today announced the firm has assisted LION bioscience AG (Nasdaq: LEON), a leading provider of integration solutions for the life science industry, in the sale of certain assets. LION announced that it has signed a definitive agreement to sell its library of more than 400 thousand compounds to Norak Biosciences, Inc. The sale, which is subject to certain closing conditions, is anticipated to close in the second quarter of 2003. Madison Keats represented LION bioscience in the transaction.

About Madison Keats
Madison Keats is a life science investment bank. The firm provides advisory services and focuses on orchestrating technology licensing, creative financing, and mergers and acquisitions. Madison Keats works exclusively within the life sciences industry. Headquartered in Charlotte, North Carolina, the firm is strategically situated in the second largest banking center in the U.S. and within close proximity to Research Triangle Park in North Carolina. For additional information, please visit www.madisonkeats.com.

About LION bioscience AG
LION bioscience (WKN 504 350, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. LION's performance software solutions developed by its scientific and IT experts enable researchers to simultaneously compile and analyze data across various phases of the R&D process. Research time and costs are reduced, as scientists are able to identify and focus on the most promising drug candidates earlier. LION (http://www.lionbioscience.com) sets the standard for integration solutions with more than 200 corporate and academic customers globally including AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Eli Lilly, GlaxoSmithKline, IBM, Incyte, Johnson & Johnson, Merck Inc., Nestlé, Novartis, Schering AG and Sumitomo Pharmaceuticals.

About Norak Biosciences, Inc.
Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor® technology to become a world leader in the discovery and development of drugs that regulate G protein- coupled receptors. For near-term growth and revenue, Norak is offering access to its technology to the drug discovery industry via licensing and screening collaborations. Norak has now acquired >800,000 compounds and high throughput screening instrumentation to discover GPCR-based drugs for its own pipeline and its partners.




This article courtesy of http://www.Aslansland.com.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.

Submit Your Article